Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)

May 1, 2026 6:52 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $237.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments